The multinational Phase III clinical trial INSPIRE tecemotide trial in Asian NSCLC patients stimulating immune response is designed to assess the efficacy of tecemotide plus BSC, compared to placebo plus BSC, on overall survival time in patients of East Asian ethnicity with locally advanced, unresectable stage III NSCLC who had documented stable disease or an objective response following completion of primary CRT based on Response Evaluation Criteria in Solid Tumors RECIST criteria <a href=https://clomid.mom/>clomid oral tablet 50 mg order online</a> Side effects of LDN treatment are reported to be mild